EGFR and neoplasm: The data suggest that classic chemotherapy combined with a TME‐targeting agent can induce tumor responses more dramatically than chemotherapy alone, and the efficacy of an AREG‐specific monoclonal antibody is even superior to cetuximab, an anti‐EGFR antibody widely applied to restrain EGFR+ neoplastic cell expansion by promoting their apoptosis in clinical patients (Mancini et al., 2017).